Do you change systemic endocrine therapy for a patient who progresses only in the brain after SRS for metastatic HR+ breast cancer?
She has no other site of disease progression and has been on an aromatase inhibitor (progressed in the CNS while on a study with adjuvant abemaciclib).
Community PollStarted
Would you change treatment (abemaciclib + AI) for a patient with metastatic ER+ breast CA who progresses only in the brain after SRS is completed?
24 physicians have voted
Join Mednetto vote and see how they answered.
1 Answer
Mednet MemberInvited Expert
Medical Oncology · Baptist Health South Florida
Answered on
No, I would continue the same hormonal therapy until systemic progression. The brain is a sanctuary site. Disappointing that abemaciclib did not prevent since it crosses b-b barrier.
Join for free or sign in to see the full answer